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Abstract 
Although strains of attenuated Salmonella typhimurium and wild-type Escherichia coli show similar 
tumor-targeting capacities, only S. typhimurium significantly suppresses tumor growth in mice. The 
aim of the present study was to examine bacteria-mediated immune responses by conducting 
comparative analyses of the cytokine profiles and immune cell populations within tumor tissues 
colonized by E. coli or attenuated Salmonellae. CT26 tumor-bearing mice were treated with two 
different bacterial strains: S. typhimurium defective in ppGpp synthesis (ΔppGpp Salmonellae) or 
wild-type E. coli MG1655. Cytokine profiles and immune cell populations in tumor tissue colonized 
by these two bacterial strains were examined at two time points based on the pattern of tumor 
growth after ΔppGpp Salmonellae treatment: 1) when tumor growth was suppressed (‘suppression 
stage’) and 2) when they began to re-grow (‘re-growing stage’). The levels of IL-1β and TNF-α 
were markedly increased in tumors colonized by ΔppGpp Salmonellae. This increase was associ-
ated with tumor regression; the levels of both IL-1β and TNF-α returned to normal level when the 
tumors started to re-grow. To identify the immune cells primarily responsible for Salmonel-
lae-mediated tumor suppression, we examined the major cell types that produce IL-1β and TNF-α. 
We found that macrophages and dendritic cells were the main producers of TNF-α and IL-1β. 
Inhibiting IL-1β production in Salmonellae-treated mice restored tumor growth, whereas tumor 
growth was suppressed for longer by local administration of recombinant IL-1β or TNF-α in 
conjunction with Salmonella therapy. These findings suggested that IL-1β and TNF-α play important 
roles in Salmonella-mediated cancer therapy. A better understanding of host immune responses in 
Salmonella therapy may increase the success of a given drug, particularly when various strategies 
are combined with bacteriotherapy. 
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Introduction 
Bacteria-mediated cancer therapy (BCT) was first 
introduced in the mid-19th century, when bacteria 
were used to treat solid tumors [1]. This approach has 
several advantages over other conventional therapies: 
bacteria have the ability to target tumors specifically; 
they actively proliferate in a variety of malignant tu-
mors; they are easy to manipulate at the genetic level; 
and they are inexpensive to produce [2]. A number of 
obligatory and facultative bacteria, such as Clostridium 
[3-6], Salmonella typhimurium [7-11], Bifidobacterium 
[12], Escherichia coli [13, 14], and Listeria [15] preferen-
tially localize, proliferate, and produce anti-cancer 
molecules in solid tumors. Although BCT is a prom-
ising strategy for cancer treatment, the actual mecha-
nisms that suppress tumor growth are unclear.  
We previously showed that two bacterial strains, 
E. coli K-12 strain (MG1655) and attenuated S. typhi-
murium defective in the synthesis of ppGpp (ΔppGpp 
S. typhimurium) have tumor-targeting ability and de-
veloped diverse BCT strategies based on these strains 
[9, 13, 14, 16-20]. Of these two strains, only ΔppGpp 
Salmonellae significantly suppressed tumor growth [9, 
14]. Thus, the following questions arise: why do these 
two bacterial strains have different tu-
mor-suppressing abilities? Might the difference be 
related to the triggering of different host immune re-
sponses? If so, what kind of immune response is 
triggered by Salmonella? 
One possible answer is that different bacterial 
strains induce different cytokine profiles in the tumor 
microenvironment. Bacteria (or bacterial components) 
induce immune responses by increasing the produc-
tion of pro-inflammatory cytokines and by activating 
different immune cell populations [21]. For example, 
gram-negative bacteria such as Salmonellae and E. coli 
express lipopolysaccharide (LPS), which is the ligand 
for TLR4 (LPS triggers inflammatory reactions and the 
secretion of pro-inflammatory cytokines [22, 23]). 
The role of TNF-α in BCT has been studied [22, 
24, 25]. TNF-α induced tumoricidal effects associated 
with gram-negative tumor-colonizing bacteria; thus 
this does not explain the contrary results achieved 
with the two different gram-negative strains. To date, 
although several studies reported underlying mecha-
nism of tumor regression upon bacterial injection, it 
has not been suggested clearly for involvement of 
other immune modulators, except TNF-α [26]. 
Although ΔppGpp Salmonellae suppressed tumor 
growth, the effect was not permanent. Tumor growth 
was significantly reduced for several days (1–10 
days), but the tumor began to re-grow after this time. 
Therefore, we examined bacteria-mediated immune 
responses by comparing the cytokine and immune 
cell profiles in tumor tissues colonized by E. coli or 
ΔppGpp Salmonellae during two separate time peri-
ods: the period of tumor suppression (‘suppression 
stage’) and the period of tumor re-growth 
(‘re-growing stage’). The aim was to identify the spe-
cific factors responsible for the anti-tumor immunity 
evoked by ΔppGpp Salmonellae. 
Materials and Methods 
Tumor cell line and animal model  
The murine CT26 colon adenocarcinoma cell line 
was obtained from the American Type Culture Col-
lection (CRL-2638). The cells were grown at 37°C/5% 
CO2 in complete DMEM (cDMEM, endotoxin-free 
DMEM high glucose medium [Hyclone, Thermal 
scientific] supplemented with 10% FBS [Gib-
co-Invitrogen] and 1% penicillin and streptomycin 
[Gibco-Invitrogen]).  
Male BALB/c mice (4–5 weeks old) were pur-
chased from Orient BIO (Charles River Laboratories, 
Korea) and maintained under specific pathogen-free 
conditions. All animal experiments conformed to the 
Chonnam National University Animal Research 
Committee protocols. CT26 cells (1 × 106) were sus-
pended in PBS and implanted subcutaneously into the 
right thigh of each mouse. Tumor volume (mm3) was 
measured with a caliper. The optimal size for analysis 
was 180 mm3. Tumor volume was measured every 3 
days until the end of experiment. Bacteria-mediated 
immune responses were examined by comparing the 
cytokine and immune cell profiles in tumor tissues 
during two separate time periods: the suppression 
stage (2 days post-inoculation, 2dpi) and the 
re-growing stage (at 15 dpi or when the tumor volume 
reached 1200 mm3). When the tumor volume ex-
ceeded 2000mm3, the animals were euthanized and 
excluded from the experiment. 
Bacterial infection  
Attenuated S. typhimurium (defective in the 
synthesis of ppGpp (RelA::cat, SpoT::kan)) expressing 
the bacterial luciferase gene lux (StΔppGpp-lux; 
SHJ2168), and wild-type E. coli MG1655 were used for 
the study [9, 13]. Mice received an intravenous injec-
tion of SLΔppGpp/lux (4.5 × 107 cells) or E. coli 
MG1655 (5 × 107 cells) in PBS, respectively. Culture, 
harvesting, and preparation of bacteria was described 
previously [19].  
Optical bioluminescence imaging 
Bioluminescence imaging was performed as 
previously described using an IVIS 100 system (Cali-
per) [19].  
Preparation of single cell suspensions 
Tumors were excised at both the suppression 
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and re-growing stages (based on the ΔppGpp Salmo-
nellae-treated group). Single cell suspensions were 
created according to the ‘Dissociation of cells from 
primary tissue’ protocol provided by Invitrogen La-
boratories. Briefly, the tumor was washed twice with 
PBS and minced into 2–3 mm3 pieces. The pieces were 
then incubated with 0.25% trypsin (Gibco-Invitrogen) 
for 2 hr at 4°C, followed by a further incubation for 20 
min at 37°C. After inactivating the trypsin, the tissue 
was ground gently, followed by filtration through 40 
µm cell strainer (Falcon) to collect digested tissues. 
Dead cells were removed by Percoll gradient centrif-
ugation (isopynic centrifugation) as previously de-
scribed [27]. Collected cells were washed with PBS 
and re-suspended in cDMEM. To obtain lymphocytes 
from the tumor-draining lymph nodes, a single cell 
suspension was first prepared, and total lymphocytes 
were suspended in RPMI (Gibco) supplemented with 
10% fetal bovine serum (Hyclone), 3 mM L-glutamine 
(Sigma), 10 mM HEPES (Sigma), 100 U/ml penicillin 
(Sigma), 100 U/ml streptomycin (Sigma), and 0.05 
mM 2-beta-mercaptoethanol (Sigma). 
mRNA isolation, cDNA synthesis, and quanti-
tative RT-PCR (qRT-PCR)  
Cells isolated from the tumor were homogenized 
in TRIzol Reagent (Molecular Research Center), and 
mRNA was obtained following the recommended 
protocol. To generate cDNA, 1 μg of total mRNA was 
firstly mixed with oligo (dT) primers (Promega, USA) 
and incubated at 65°C for 5 min. The primer/template 
mix was chilled on ice and reaction mix containing 
Improm-II Reverse Transcriptase (Promega) was 
added. The samples were then incubated at 30°C for 
10 min, followed by 42°C for 60 min, and 70°C for 15 
min in PCR Thermal Cycler Dice machine (Takara, 
Japan). cDNA was amplified using the RT-PCR pri-
mer sets listed in the Table 1. PCR reactions were 
performed in Rotor-Gene 3000 (Corbett Robotics, 
Australia). SYBR Premix Ex Taq (Takara) was used to 
detect amplification under the following conditions: 
10 min at 95°C, followed by 40 three-temperature cy-
cles (15 s at 95°C, 30 s at 60°C, and 15 s at 72°C). All 
reactions were run in triplicate. Results were analyzed 
with Rotor-Gene Software. HPRT was used as 
housekeeping gene to assess target gene expression.  
Western blot analysis  
To measure the amount of pro-IL-1β and caspa-
se-1, isolated tumor cells were lysed in protein ex-
traction solution (Intron Biotechnology), subjected to 
SDS-PAGE, and subsequently transferred to a nitro-
cellulose membrane (Bio-Rad). The membranes were 
probed with polyclonal goat anti-mouse IL-1β 
(AF-401-NA, R&D Systems; 1:2000 dilution) or poly-
clonal rabbit anti-mouse caspase-1 (sc-514, Santa Cruz 
Biotechnology; 1:1000 dilution) antibodies, followed 
by horseradish peroxidase-conjugated donkey an-
ti-goat IgG (sc-2020, Santa Cruz Biotechnology; 1:2000 
dilution) or polyclonal goat anti-rabbit IgG/HRP 
(P0448, Dako; 1:2000 dilution), respectively. Biolumi-
nescence was catalyzed using a Western Blotting 
Luminol Reagent (Santa Cruz), and bands were de-
tected in a luminescent image analyser LAS-3000 (Fu-
jifilm). 
Table 1. Primer sequences for cytokines and housekeeping genes. 
 Name Sequence (5' → 3') 
IL-1β IL-1β Forward GCA ACT GTT CCT GAA CTC AAC T 
 IL-1β Reverse ATC TTT TGG GGT CCG TCA ACT 
TNF-α TNF-α Forward CAT CTT CTC AAA ATT CGA GTG ACA A 
 TNF-α Reverse TGG GAG TAGACA AGG TAC AAC CC 
IL-6 IL-6 Forward GAG GAT ACC ACT CCC AAC AGA CC 
 IL-6 Reverse AAG TGC ATC ATC ATC GTT GTT CA 
IFN-γ IFN-γ Forward TCA AGT GGC ATA GAT GTG GAAGAA 
 IFN-γ Reverse TGG CTC TGC AGG ATT TTC ATG 
TGF-β TGF-β Forward GAA GGC AGA GTT CAG GGT CTT 
 TGF-β Reverse GGT TCC TGT CTT TGT GGT GAA 
HPRT HPRT Forward TTA TGG ACA GGA CTG AAA GAC 
 HPRT Reverse GCT TTA ATG TAA TCC AGC AGG T 
 
Measurement of cytokines in tumor tissues 
and serums 
Tumor tissues were homogenized in protein ex-
traction solution (Intron Biotechnology), and the su-
pernatant was collected by centrifugation. Blood was 
collected by cardiac puncture at 0, 0.5, 3, 12h and 2dpi 
and then serum was harvested by removing blood 
clot after centrifugation. Cytokine levels were meas-
ured using individual ELISA kits (eBioscience) ac-
cording to the manufacturer’s instructions. The sub-
strate color reaction was measured at 450 nm in an 
ELISA reader (SpectraMax, Molecular Devices). 
Flow cytometry analysis  
For surface staining, cells were washed with PBS 
and then incubated with fluorescence-labeled anti-
bodies against target cell surface molecules for 20 min 
in the dark. For intracellular staining, cells were 
re-stimulated with phorbol 12-myristate 13-acetate 
(PMA) and ionomycin (Calbiochem) in GolgiStop (1 
mg/ml; BD Biosciences) at 37℃ for 5 hours. After cells 
were stained for surface markers (see below) for 20 
min, they were fixed in IC Fixation buffer (eBioscience) 
for 30 min. Cells were then washed and re-suspended 
in permeabilization buffer (eBioscience) containing 
intracellular detection antibodies (see below) for 20 
min. To detect Foxp3 and Helios, cells stained for 
surface markers were suspended in 1 ml of fixa-
tion/permeabilization buffer for 1 hour, re-suspended 
in permeabilization buffer, and then stained with each 
of the antibodies. Cells were then washed and 
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re-suspended in PBS, and at least 10,000 events were 
analyzed using an LSR-Fortessa flow cytometer (BD 
Bioscience), according to the manufacturer’s instruc-
tions. Data were evaluated using FlowJo software 
(TreeStar). Antibodies to the following were used for 
surface staining: CD3 (17A2), CD4 (RM4-5), CD8 
(53-6.7), B220 (RA3-6B2), CD11b (M1/70), CD11c 
(N418), CD25 (PC61), CD45 (30-F11), F4/80 (BM8), 
MHCII (M5/114.15.2), CD68 (FA-11), Gr1 (RB6-8C5), 
Ly6C (HK1.4), Ly6G (1A8), CD103 (2E7), CTLA4 
(UC10-4B9), and ICOS (C398.4A) (all from BioLegend). 
The following antibodies were used for intracellular 
staining: IL-1β (NJTEN3), TNF-α (MP6-XT22), Foxp3 
(FJK-16s), and Helios (22F6) (all from eBioscience). 
Apoptosis assay 
Cells were isolated from tumor tissue and sepa-
rated using magnetic beads (Miltenyi Biotech). As 
there is no common marker for CT26 tumor cells, an-
tibodies against the following representative immune 
cell markers were used: CD4 (RM4-5), CD8 (53-6.7), 
CD19 (6D5), B220 (RA3-6B2), CD11b (M1/70), CD11c 
(N418), CD24 (M1/69), CD25 (PC61), CD49b (DX5) 
(all from BioLegend), and γδTCR (eBioCL3) (eBiosci-
ence). Cells that expressed at least one of these mole-
cules were considered to be immune cells, whereas 
those that did not were considered to be tumor cells. 
This procedure was used to examine apoptotic im-
mune cells and tumor cells isolated from tumor tis-
sues. Cells were washed with PBS and re-suspended 
in binding buffer (BD Pharmingen) prior to incuba-
tion with Annexin V and 7-AAD (BD Pharmingen). 
The populations of viable cells (Annexin V-7AAD-), 
early apoptotic cells (Annexin V+7AAD-), and late 
apoptotic or necrotic cells (Annexin V+7AAD+) were 
analyzed using an LSR-Fortessa flow cytometer (BD 
Biosciences), according to the manufacturer’s instruc-
tions. Data were evaluated using FlowJo software 
(TreeStar). 
Treatment with an anti-IL-1β antibody or re-
combinant IL-1β  
To deplete IL-1β, mice were injected with 5 μg of 
an IL-1β-specific antibody (AF401-NA, R&D Systems) 
1 day before infection by bacteria and then twice a 
week for 2 weeks thereafter. The control group re-
ceived hamster immunoglobulin (EQUITECH Bio) 
according to the same schedule. The Salmonellae and 
IL-1β combination therapy groups received an intra-
tumoral injection of recombinant IL-1β (0.5 μg; 
401-ML/CF, R&D Systems) suspended in PBS every 2 
days starting at 5 dpi and continuing until 11 dpi. 
Recombinant IL-1β was injected using a Microliter 
syringe (Hamilton Company) fitted with a Preci-
sionGlide Needle (BDM011455-1, BD Bioscience). 
Treatment with an anti-TNF-α antibody or 
recombinant TNF-α 
Procedures similar to those described for the an-
ti-IL-1β antibody or recombinant IL-1β were used. To 
deplete TNF-α, mice were injected with 50 μg of a 
TNF-α-specific antibody (AF410-NA; R&D Systems) 1 
day before infection by bacteria and then twice per 
week for 2 weeks thereafter. The Salmonellae and 
TNF-α combination therapy groups received an in-
tratumoral injection of recombinant TNF-α 
(410-MT/CF; 0.25 μg in PBS; R&D Systems) every 2 
days starting at 5 dpi and continuing until 11 dpi. 
Recombinant TNF-α injections were performed using 
a Microliter syringe (Hamilton Company) fitted with 
a PrecisionGlide Needle (BDM011455-1; BD Biosci-
ences). 
Immunohistochemistry and immunofluores-
cence staining 
Tumor tissues were excised at 2 dpi, fixed in 4% 
paraformaldehyde at 4°C for 4 hr, immersed in 30% 
sucrose/PBS overnight at 4°C, washed with PBS, and 
then embedded in OCT compound (Leica microsys-
tem) in a plastic container.  
OCT-mounted tissues were cryo-sectioned (5 
μm) using a Microm HM 525 cryotome (Thermo Sci-
entific). Sections were incubated with streptavi-
din-biotin labeled antibodies (diluted 1:100–1:500) 
against CD45 (MCA1031GA, ABD Serotec), CD68 
(MCA1957GA, ABD Serotec), Ly-6G/Ly-6C (sc-71674, 
Santa Cruz), and CD11c (550283, BD Pharmingen). 
Briefly, sections were rehydrated in cold acetone for 
15 min and washed with PBS. Endogenous peroxidase 
activity and non-specific binding were blocked with 
0.3% H2O2 and 5% BSA in TBS containing 0.1% Tween 
20, respectively. After blocking, the sections were in-
cubated with the primary antibody overnight at 4°C, 
followed by the appropriate secondary antibody for 2 
hr at room temperature. Nuclei were stained with 
hematoxylin. Finally, the sections were mounted in 
Immu-Mount reagent (238402, Thermo Scientific).  
For immunofluorescence staining, tissues sec-
tions were permeabilized and blocked with TBS con-
taining 0.1% Tween 20, 0.3% Triton X-100, and 5% 
BSA. The sections were then incubated with rat an-
ti-neutrophil antibodies (sc-71674, Santa Cruz), rat 
anti-CD68 (MCA1957GA, ABD Serotec), hamster an-
ti-CD11c (550283, BD Pharmingen), rabbit anti-IL-1β 
(sc-7884, Santa Cruz), or goat anti-TNF-α (sc-1350, 
Santa Cruz) overnight at 4°C. Alexa Fluor 488 donkey 
anti-rat (A21208), Alexa Fluor 555 donkey anti-rabbit 
(A31572), Alexa Fluor 568 goat anti-hamster (A21112), 
Alexa Fluor 488 goat anti-rabbit (A11008), Alexa Fluor 
555 donkey anti-goat (A21432), and Alexa Fluor 488 
donkey anti-goat (A11055) antibodies were used as 
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secondary antibodies (all from Invitrogen). All anti-
bodies were diluted to 1:200 in TBS containing 0.1% 
Tween 20, 1% BSA, and 0.1% Triton X-100. Samples 
were mounted with Pro-long® Gold antifade reagent 
(P36930, Invitrogen) and analyzed under a 
Fluoview-1000 (FV-1000) laser scanning confocal mi-
croscope (Olympus).  
Statistical analysis  
All statistical analyses were performed using 
Excel and SPSS 15.0 software. The results are ex-
pressed as the mean ± SD. Data were analyzed using 
an independent t-test. P < 0.05 was considered signif-
icant. 
Results 
Salmonellae inhibit tumor growth 
First, we examined the tumor-targeting activity 
of MG1655 and ΔppGpp Salmonellae in BALB/c mice 
bearing subcutaneous CT26 colon carcinomas. Both 
MG1655 and ΔppGpp Salmonellae showed similar 
tumor-targeting and proliferative capabilities when 
injected intravenously (i.v.) into tumor-bearing mice 
[9, 13] (Fig. 1A and S1A).  
Injection of ΔppGpp Salmonellae led to significant 
suppression of tumor growth for around 10 dpi; 
however, the tumors tended to re-grow (Fig. 1B, C). 
By contrast, tumors infected with MG1655 grew at the 
same rate as non-treated tumors. Based on the results 
observed for ΔppGpp Salmonellae, we divided the 
tumor growth curve into two phases: the period of 
tumor suppression (‘suppression stage’, 1–10 dpi) and 
the period of tumor re-growth (‘re-growing stage’, 
≥15 dpi). As previously reported [28], tumors colo-
nized by Salmonellae showed massive hemorrhage and 
necrosis during the suppression stage (Fig. 1C).  
 
Figure 1. Systemic injection of ΔppGpp Salmonellae (SLΔppGpp) into tumor-bearing mice induces significant growth suppression compared with E. coli 
(MG1655) or PBS injection. Mice (n = 5/group) were subcutaneously injected (into the right thigh) with CT26 cells (1 × 106). When the tumor volume reached 180 mm3, mice 
received an intravenous (i.v.) injection of PBS, MG1655 (5 × 107 CFU), or SLΔppGpp (4.5 × 107 CFU). (A) Distribution of bacteria visualized by in vivo bioluminescence imaging 
after injection of bacteria expressing bacterial luciferase (lux). (B) Tumor volume was then measured every 3 days until the end of experiment. The dotted line represents 
maximum tumor volume; mice were sacrificed when the tumor volume reached 2000mm3. Growth stages were divided into two phases based on the pattern of tumor growth 
after SLΔppGpp treatment; the suppression stage is the period during which the tumor stopped growing and/or shrunk in size, whereas the re-growing stage is the period during 
which the tumor grew again in SLΔppGpp-treated mice. (C) Images of the tumor graft in CT26-bearing mice. The shape of the tumor was noted before (0 dpi) and after treatment 
with PBS or bacteria (2 and 5 dpi). (D) Two days after treatment, cells were isolated from the tumor and the degree of apoptosis was measured using annexin V and 7AAD. 
Isolated cells were then separated into tumor cells and infiltrating immune cells to identify the cells in which apoptosis was induced. Thus, infiltrated immune cells were isolated 
by magnetic bead method using representative immune cell markers including CD4, CD8, CD19, B220, CD11b, CD11c, CD24, CD25, CD49b, and γδTCR. Apoptotic popu-
lations were investigated in two types of cells; immune cells and tumor cells isolated from tumor tissue. Data represent the mean ± SD of three independent experiments. *P < 
0.05, **P < 0.005, and ***P < 0.001 vs. the control at Day 9 and 12 and vs. MG1655 at Day 15. 
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Next, we measured the amount of cell death. 
Cells isolated from the tumor mass during the sup-
pression stage and re-growing stage were stained 
with markers of early and late apoptosis (annexin V 
and 7-aminoactinomycin (7-AAD), respectively). Iso-
lated cells were then separated into tumor cells and 
infiltrating immune cells using magnetic beads and 
antibodies against representative immune cell mark-
ers (CD4, CD8, CD19, B220, CD11b, CD11c, CD24, 
CD25, CD49b, and γδTCR). Cells expressing at least 
one of these molecules were considered to be immune 
cells, whereas cells that did not were considered to be 
tumor cells. Apoptosis of immune cells and tumor 
cells was also examined (Fig. 1D). Compared with 
control and MG1655-treated tumors, a significant 
population of tumor cells was apoptotic within the 
ΔppGpp Salmonellae-treated tumors. The number of 
apoptotic tumor cells significantly decreased to low 
level during the re-growing stage in control, 
MG1655-, and ΔppGpp Salmonellae-treated tumors 
(Fig. S2A). On the other hand, the number of apop-
totic immune cells in control, MG1655-, and ΔppGpp 
Salmonellae-treated tumors was not significantly dif-
ferent. These results suggest that the tu-
mor-suppressive activity of ΔppGpp Salmonellae is 
responsible for the different levels of apoptosis in-
duction observed at the suppression and re-growth 
stages. 
Increased infiltration of immune cells into 
tumors colonized by ΔppGpp Salmonellae  
We next examined immune cell infiltration into 
tumors colonized by bacteria. We found that ΔppGpp 
Salmonellae treatment led to increased infiltration of 
tumor tissues by leukocytes (CD45+), including mac-
rophages (CD11b+F4/80+ or CD68+), dendritic cells 
(DCs, CD11c+MHCII+), CD8+ T cells (CD3+CD8+), B 
cells (B220/CD45R+MHCII+), and neutrophils 
(CD11b+Gr1+ or Ly-6G/Ly-6C+) (Fig. 2A-C). Con-
sistent with previous studies [24, 29-31], we found 
that infiltrated neutrophils accumulated at the border 
between the proliferative and necrotic areas of tumors 
colonized by ΔppGpp Salmonellae; however, only 
clusters of neutrophils were observed in tumors colo-
nized by MG1655 (Fig. S3A). We also found that the 
numbers of neutrophils, macrophages, and DCs in the 
tumor-draining lymph nodes (tLNs) or spleens were 
higher in mice injected with ΔppGpp Salmonellae than 
in mice injected with MG1655 or in control mice, re-
spectively (Fig. S3B, C). 
We next used multi-color flow cytometry to 
further investigate the characteristics of macrophages 
and myeloid-derived suppressor cells (MDSCs) iso-
lated from tumor tissue (Fig. S2A, C). To differentiate 
between M1 and M2 macrophages, we examined 
CD68 and Ly6C expression in CD11b+ F4/80+ cells 
[32]. The M1-like population (CD68intLy6Cint) in tu-
mors colonized by ΔppGpp Salmonellae increased, 
whereas the M2-like population (CD68hiLy6Chi) was 
similar between groups (Fig. 2C). To examine the 
MDSC population, we gated on the CD11b+ cell 
population and then examined the expression of Ly6C 
and Ly6G [33]. Each MDSC subset within the mono-
cytic MDSC (M-MDSC) and polymorphonuclear 
MDSC (PMN-MDSC) populations were examined 
according to their expression of Ly6C and Ly6G 
(M-MDSC: CD11b+Ly6ChiLy6G-; PMN-MDSC: 
CD11b+Ly6Clow/intLy6G+). The overall population of 
MDSCs within the tumor was not significantly dif-
ferent after infection by ΔppGpp Salmonellae (Fig. 2C).  
At the re-growing stage, the proportion of infil-
trating immune cells within tumors colonized by 
ΔppGpp Salmonella was comparable with that in tu-
mors colonized by MG1655 or control tumors (Fig. 
S2B, C). In addition, the proportion of M1/M2 mac-
rophages and MDSC was similar among all groups.  
We also tested whether treatment with ΔppGpp 
Salmonellae induced changes in the regulatory T cell 
(Treg) population. Although the function of Tregs 
during tumor progression is still unclear, increased 
Treg numbers within tumors are thought to indicate a 
poor prognosis [34]. Thus, we examined whether the 
number and characteristics of Tregs are affected by 
ΔppGpp Salmonellae. We examined Treg cell charac-
teristics by analyzing the expression of known Treg 
markers, including CD25, CTLA4, CD103, and ICOS, 
along with Helios (a thymic Treg marker) [35, 36]. 
Tumors colonized by ΔppGpp Salmonellae showed 
reduced expression of these markers at the suppres-
sion stage (Fig. S4A); however, the expression levels 
increased at the re-growing stage, reaching levels 
similar to those in control tumors or tumors colonized 
by MG1655 (Fig. S4B). These results suggest that 
ΔppGpp Salmonellae induce tumor suppression not 
only by increasing tumor-infiltrating immune cells 
such as M1 macrophages, neutrophils, DCs, CD8 T 
cells and B cells, but also by reducing both the Treg 
population and Treg effector function, mainly in tu-
mor-bearing regions. 
The production of IL-1β and TNF-α is elevated 
in tumors colonized by ΔppGpp Salmonellae  
Because different immune cell populations ac-
cumulated in tumors colonized by Salmonellae, we 
speculated that effector molecules produced by these 
infiltrating cells might be involved in the observed 
tumor-suppressive effects. Thus, we next explored 
immunological changes in the tumor, focusing on 
cytokines that regulate the survival, proliferation, and 
differentiation of both immune cells and tumor cells. 
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Tumor-bearing mice were treated with ΔppGpp Sal-
monellae, MG1655, or PBS, and cells were isolated at 
the suppression stage and re-growing stage. First, we 
examined the cytokine profiles using RT-PCR. We 
found that there was a marked increase in the amount 
of IL-1β and TNF-α transcripts in ΔppGpp Salmonel-
lae-infected tumors; however, the levels of transcripts 
for other cytokines related to tumor development 
(IL-6, IFN-γ, and TGF-β) were similar to those in con-
trol tumors (Fig. 3A). There was no significant dif-
ference between the expression of these cytokines in 
MG1655-infected tumors and control tumors.  
 
 
Figure 2. Colonization by SLΔppGpp leads to increased tumor infiltration by immune cells. (A) Tumor infiltration by immune cells was examined by immuno-
histochemistry at 2 dpi. Tumor tissue was stained for CD45, Ly-6G/Ly-6C, CD68, and CD11c, which are surface markers for hematopoietic cells, neutrophils, macrophages, and 
dendritic cells, respectively. Positive cells are brown. Sections were counterstained with hematoxylin. (B) Tumor-infiltrating cells were analyzed by flow cytometry. The indicated 
percentages represent hematopoietic cells (CD45+), neutrophils (CD11b+Gr1+), macrophages (CD11b+F4/80+), and dendritic cells (CD11c+MHCII+), respectively. (C) The 
indicated numbers represent the proportion of CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), and B cells (B220+MHCII+) within CT26 tumors. The population of 
M1/M2 macrophages was examined by measuring CD68 and Ly6C expression in CD11b+F4/80+ cells (M1: CD68intLy6Cint, M2: CD68hiLy6Chi). MDSCs within CD11b+ cell 
population was also categorized M-MDSC (monocytic MDSC, CD11b+Ly6ChiLy6G-) and PMN-MDSC (polymorphonuclear MDSC, CD11b+Ly6ClowLy6G+). Data are repre-
sentative of two individual experiments, each showing similar results. 
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Figure 3. Cytokine profile in SLΔppGpp- or MG1655-colonized tumors during the suppression stage. (A) Cells were isolated from tumors at 2dpi, and the 
expression of different cytokines was analyzed by qRT-PCR. HPRT was used as housekeeping gene to assess target gene expression. (B) Tumors were excised and homogenized 
in protein extraction solution, and the level of cytokines in the supernatant was measured by ELISA. (C) Single cell suspensions derived from tumor tissues were lysed, and total 
protein was obtained. The expression of caspase-1, pro-IL-1β, IL-1β, IL-18 and IPAF was examined by western blotting. β-actin was used as the loading control. (D) Serum TNF-α 
levels were measured in an ELISA at the indicated times. Data represent the mean ± SD. *P < 0.05, **P < 0.005, and ***P < 0.001. 
 
We next measured the expression of cytokines at 
the protein level. Again, IL-1β and TNF-α were highly 
expressed in ΔppGpp Salmonellae-infected tumors 
compared with non- or M1655-infected tumors. The 
expression of IL-6 and TGF-β in the ΔppGpp Salmo-
nellae group was comparable with that in the control 
and MG1655 groups. The level of IFN-γ in the 
ΔppGpp Salmonellae group was about twice that in the 
control group; however, it was not as significant as 
IL-1β and TNF-α (Fig. 3B).  
Previous studies highlighted the role of TNF-α in 
bacteriotherapy [22, 24, 25]; however, none reported 
changes in IL-1β expression. Thus, we examined 
whether the IL-1β processing pathway is activated in 
colonized tumors by comparing the levels of 
pro-IL-1β and caspase-1/IL-1 converting enzyme 
(ICE, which promotes the maturation of pro-IL-1β 
[37]) in cells from the ΔppGpp Salmonellae, MG1655, 
and PBS groups by western blotting. Strong signals 
were observed for both pro-IL-1β and caspase-1 in 
ΔppGpp Salmonellae-treated tumors, but not in 
MG1655-treated tumors (Fig. 3C). Consistent with 
pro-IL-1β production, we found that IL-1β was 
cleaved into its 17 kD mature form in ΔppGpp Sal-
monellae-treated tumors. In addition to IL-1β, we also 
detected mature IL-18 in ΔppGpp Salmonellae-treated 
tumors but not in MG1655- or PBS-treated tumors 
(Fig. 3C). The main pathway responsible for pro-
cessing IL-1β is the inflammasome, a multi-protein 
complex that forms in the cytosol and activates 
caspase-1, leading to the subsequent cleavage and 
secretion of active IL-1β. Interestingly, we found that 
expression of the core molecule involved in inflam-
masome signaling, IPAF (ICE-protease-activating 
factor), was significantly higher in ΔppGpp Salmonel-
lae-treated tumors than in MG1655- or PBS-treated 
tumors (Fig. 3C).  
We also examined whether treatment with 
ΔppGpp Salmonellae affected serum levels of IL-1β or 
other cytokines. There was no significant difference in 
the serum levels of IL-1β (data not shown) in mice 
treated with ΔppGpp Salmonellae or MG1655 at any of 
the time points tested; however, the serum levels of 
TNF-α were significantly higher in mice treated with 
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ΔppGpp Salmonellae than in mice treated with 
MG1655 at 3 h and 12 h post-bacterial injection (Fig. 
3D). 
Next, we examined whether the expression of 
these cytokines changed during the re-growing stage. 
We found that the expression of IL-1β and TNF-α 
transcripts was significantly down-regulated in 
ΔppGpp Salmonellae-treated tumors at re-growing 
stage, almost approaching the levels of the control 
group (Fig. S5A). Western blotting showed reduced 
expression of IL-1β, pro-IL-1β, and caspase-1 at this 
stage (Fig. S5B). Taken together, these results strongly 
suggest that ΔppGpp Salmonellae suppresses tumor 
growth by increasing the expression of IL-1β and 
TNF-α. 
Dendritic cells and macrophages are respon-
sible for increased IL-1β and TFN-α levels in 
tumors colonized by ΔppGpp Salmonellae  
Monocyte lineage cells (macrophages in partic-
ular) may be the main sources of pro-inflammatory 
IL-1β and TNF-α [22, 38]. We next tried to identify the 
cells within colonized tumors responsible for pro-
ducing these two cytokines. First, we double stained 
macrophages (CD68), neutrophils (Ly-6G/Ly-6C) or 
DCs (CD11c) for IL-1β or TNF-α and examined them 
under an immunofluorescence (IF) microscope. Sec-
ond, we performed flow cytometry analysis using 
isolated cells from tLNs and spleens to identify and 
quantify IL-1β/TNF-α-producing cells. We could not 
collect data from the tumor region in the ΔppGpp 
Salmonellae-treated group because cells were either 
dying or already dead. Instead, we analyzed IL-1β 
and TNF-α expression in the tLNs and spleen. The 
IL-1β- and TNF-α-producing cells within the total cell, 
macrophage (CD11b+F4/80+), neutrophil 
(CD11b+Gr1+), and DC (CD11c+MHCII+) popula-
tions were analyzed after re-stimulation with PMA 
and ionomycin. 
The results showed that macrophages and DCs 
might produce IL-1β. Some macrophages co-localized 
with the IL-1β signal (Fig. 4A), while neutrophils lo-
cated beside IL-1β (Fig. 4B). Intriguingly, the pattern 
of the fluorescence signals suggested precise 
co-localization of IL-1β and DCs, indicating that most 
DCs within the tumor produce IL-1β (Fig. 4C). Flow 
cytometry analysis supported the IF microscopic 
findings showing that treatment with ΔppGpp Sal-
monellae led to a significant increase in IL-1β expres-
sion by DCs and macrophages in tLNs and the spleen 
(Fig. 4D, E). Thus, although DCs may not be the only 
producer of IL-1β, they appear to be the main pro-
ducer in response to Salmonellae colonization.  
Next, we identified the immune cells that secrete 
TNF-α in bacteria-infected tumors. As shown previ-
ously, IF double-staining revealed that most CD68+ 
macrophages co-localized with the TNF-α signals in 
ΔppGpp Salmonella-infected tumors; however, some 
macrophages co-localized with TNF-α signals in 
MG1655-infected tumors (Fig. 5A). This clearly sug-
gests that macrophages are the main producers of 
TNF-α in response to bacterial colonization. There 
was no correlation between the localization of neu-
trophils or DCs and TNF-α signals (Fig. 5B, C). Quan-
titative analysis by intracellular flow cytometry also 
revealed a significant increase in TNF-α expression by 
macrophages (Fig. 5D, E). Taken together, these re-
sults suggest that TNF-α and IL-1β in ΔppGpp Sal-
monellae-colonized tumors are mainly produced by 
CD68+ macrophages and CD11c+ DCs, respectively. 
Inhibiting IL-1β production reduces the ther-
apeutic efficacy of ΔppGpp Salmonellae, but 
co-treatment with recombinant IL-1β or 
TNF-α increases the therapeutic efficacy  
The anti-cancer activity of TNF-α is considered a 
promising target for BCT [25, 39, 40]. Here, we exam-
ined the role of IL-1β in Salmonella-mediated cancer 
therapy by blocking its activity with an anti-IL-1β 
antibody (Fig. 6A). An anti-IL-1β antibody abrogated 
the anti-tumor activity of ΔppGpp Salmonellae in tu-
mor-bearing mice (Fig. 6B, C). Co-injection of an iso-
type control antibody (hamster IgG) did not abrogate 
the anti-tumor effect. 
We next asked whether injecting recombinant 
IL-1β would increase the anti-tumor effects of 
ΔppGpp Salmonellae. Intratumoral injection of recom-
binant IL-1β from 5 dpi (followed by re-injection 
every 2 days) prolonged the tumor-suppressive activ-
ity of ΔppGpp Salmonellae (tumor growth remained 
suppressed until the end of the experiment). Howev-
er, injection of recombinant IL-1β alone had only a 
mild suppressive effect compared with PBS (Fig. 6B, 
C). Treatment with an anti-IL-1β antibody or recom-
binant IL-1β did not lead to significant changes in the 
number of bacteria when compared with ΔppGpp 
Salmonellae treatment alone (Fig. S1C). Thus, neither 
recombinant IL-1β nor an anti-IL-1β antibody regu-
lates the persistence of ΔppGpp Salmonellae in tumor 
tissue. 
Considering that TNF-α has the potential to both 
stimulate and suppress tumor growth, we also ex-
amined its effect on tumor growth. Co-treatment with 
recombinant TNF-α prolonged the tumor-suppressive 
effects of ΔppGpp Salmonellae (Fig. S6A, B) in a man-
ner similar to that observed after treatment with re-
combinant IL-1β (Fig. 6B, C). These results strongly 
suggest that both IL-1β and TNF-α play an important 
role in Salmonella-mediated cancer therapy. 
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Figure 4. Analysis of IL-1β producing cells. Tumor tissue was excised and fixed at 2 dpi, cryo-sectioned, and immunostained for IL-1β plus CD68 (macrophages), 
Ly-6G/Ly-6C (neutrophils), or CD11c (dendritic cells). Representative images from three independent experiments are shown (A–C). The green signal represents CD68 (A), 
Ly-6G/Ly-6C (B), or CD11c (C), whereas the red signal represents IL-1β. Sections were stained with DAPI (blue signal) as a control. Scale bar = 50 µm. (D, E) Cells were 
re-stimulated with PMA and ionomycin in the presence of GolgiStop, and the IL-1β+ population was examined by intracellular staining. Multi-color analysis was used to examine 
the proportion of IL-1β+ cells within the total cell, macrophage (CD11b+F4/80+), neutrophil (CD11b+Gr1+), and dendritic cell (CD11c+MHCII+) populations. The indicated 
values represent the IL-1β+ population in the tumor-draining lymph nodes (D) and spleen (E). Data are representative of two individual experiments, each with similar results. 
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Figure 5. Analysis of TNF-α producing cells. TNF-α expression in tumor tissue at 2 dpi was examined as described in the legend to Figure 4, except cells were stained for 
TNF-α (red) rather than IL-1β. Representative images from three independent experiments are shown (A–C). DAPI was used as a control. Scale bar = 100 µm. (D, E) Cells were 
re-stimulated with PMA and ionomycin in the presence of GolgiStop and the TNF-α+ cell population examined by intracellular staining. Multi-color analysis was used to examine 
the proportion of TNF-α+ cells within the total cell, macrophage (CD11b+F4/80+), neutrophil (CD11b+Gr1+), and dendritic cell (CD11c+MHCII+) populations. The indicated 
values represent the TNF-α+ population in the tumor-draining lymph nodes (D) and spleen (E). Data are representative of two individual experiments, each with similar results. 
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Figure 6. Role of IL-1β in SLΔppGpp-mediated cancer therapy. (A) Protocols for co-treatment with an IL-1β blocking antibody (left) or recombinant IL-1β (right), plus 
PBS or SLΔppGpp. (B) CT26 cells were transplanted into mice. Mice then received an intravenous (i.v.) injection of PBS (black rectangles) or SLΔppGpp (black circles). IL-1β 
depletion: mice received an i.v. injection of anti-IL-1β-specific antibody (IL-1β Ab) 1 day before SLΔppGpp treatment (Day 1). The antibody was then injected twice a week for 
2 weeks (open rectangles). Control mice received isotype (IgG) according to the same schedule (black triangles). Treatment with recombinant IL-1β (rIL-1β): mice received an 
intratumoral (i.t.) injection of rIL-1β on 5 dpi (open triangles), followed by another i.t injection every other day up until 11 dpi. Another group of tumor-bearing mice received 
four i.t injections of rIL-1β alone (open circles). Data represent the mean ± SD. Results from at least three individual experiments are shown. *P < 0.05, **P < 0.005, and ***P < 
0.001 vs. control at Day 12 and vs. SLΔppGpp at Day 18. (C) Photographs of representative animals in each group were taken before (0 dpi) and after treatment (5 and 16 dpi). 
 
Discussion 
The present study showed that tumor coloniza-
tion by ΔppGpp Salmonellae led to significant in-
creases in the amount of IL-1β and TNF-α within the 
tumor mass, particularly during the tumor suppres-
sion stage. Tumor colonization by ΔppGpp Salmonel-
lae led to increased infiltration of the tumor by host 
immune cells, which in turn led to increased expres-
sion of IL-1β and TNF-α by DCs and macrophages. 
Taken together these results suggest that increased 
expression of IL-1β and TNF-α mediates a protective 
anti-cancer immune response via ΔppGpp Salmonel-
lae. 
ΔppGpp Salmonellae treatment led to a signifi-
cant increase in tumor infiltration by leukocytes such 
as macrophages, DCs, neutrophils, CD8+ T cells, and 
B cells. Colonization and proliferation of ΔppGpp 
Salmonellae significantly increased the proportion of 
M1-like macrophages and reduced Treg numbers in 
tumor tissue during the suppression period. These 
changes were reversible; the numbers of M1-like 
macrophages and Treg cells were similar to those in 
MG1655-treated or control tumor during the 
re-growing stage. This implies that ΔppGpp Salmo-
nellae suppress tumor growth by making intratumoral 
myeloid cells less suppressive and by enhancing the 
anti-tumor immune response. Indeed, a previous 
study showed that the anti-tumor effects of Salmo-
nella depend on a functional MyD88-TLR pathway, 
and that Salmonella treatment significantly reduces 
the intratumoral myeloid cell population [41]. 
TNF-α is involved in apoptosis-induced tumor 
cell death [42-44]; thus its role in BCT has been exten-
sively investigated [24, 25, 45]. The rapid increases of 
circulating TNF-α induced by bacterial infection may 
make tumor vessels hyper-permeable, resulting in 
rapid influx of blood into the tumor due to vascular 
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disruption [24]. A previous study shows that admin-
istration of TNF-α with chemotherapy enhanced tu-
mor-selective drug uptake during perfusion and re-
vealed high response rates in soft tissue sarcoma pa-
tients [46]. Here, we found that co-administration of 
recombinant TNF-α prolonged the tumor-suppressive 
effects of ΔppGpp Salmonellae. 
Here, we showed that tumor-infiltrating cells 
produced large amounts of IL-1β in response to i.v. 
injection of ΔppGpp Salmonellae, leading to sup-
pressed tumor growth; however, IL-1β levels returned 
to baseline when the tumor started to re-grow. A re-
cent study showed that certain types of tumor cell 
produce high levels of IL-1β, which recruits tu-
mor-associated neutrophils (TANs) to the site (TANs 
play a crucial role in anti-tumor activity) [47]. In ad-
dition, we found that immune cells, in particular DCs, 
are the main source of IL-1β in colonized tumors. 
Several mechanisms are responsible for processing 
IL-1β, including the caspase-1-dependent pathway 
(monocytes [48], macrophages [48], and dendritic cells 
[49]) and the caspase-1-independent pathway (mon-
ocytes [50] and neutrophils [51]) [52]. Here, we ex-
amined the expression of molecules associated with 
the inflammasome. We found that expression of the 
core molecules involved in the inflammasome sig-
naling pathway, such as IPAF, caspase-1, IL-18, and 
IL-1β were up-regulated in ΔppGpp Salmonel-
lae-treated tumors. Several nod-like receptor 
(NLR)-family proteins, including IPAF and NLRP3, 
are thought to regulate caspase-1 activation [49]. 
Franchi et al. showed that activation of caspase-1 in 
response to Salmonellae invasion was triggered by 
cytosolic exposure to bacterial flagellin; caspase-1 
activation was mediated via IPAF signaling and was 
independent of TLR signaling [53].  
Although chronic exposure to IL-1β is thought to 
play a role in angiogenesis and invasion in some 
cancers [54-57], the cytokine was also successfully 
used to treat cancer [22, 49, 58-61]. For example, a 
previous study suggests that DC-derived IL-1β in-
duces tumor cell death by priming CD8+ T lympho-
cytes or promoting the polarization of CD4+ T cells 
into Th1 cells, which is crucial for a therapeutic re-
sponse [49]. Because chemotherapeutic agents are 
cytotoxic, tumor cells release ‘danger signals’, which 
then activate the inflammasome complex 
(NLRP3-ASC-Caspase-1) in DCs, thereby triggering 
the maturation of caspase-1 [62]. Hence, IL-1β is a 
potential treatment for cancer.  
Notably, the data presented herein show that 
blocking IL-1β activity abrogated the anti-tumor ef-
fects of ΔppGpp Salmonellae. Thus, IL-1β has potential 
anti-cancer activity in the context of BCT. Treatment 
with ΔppGpp Salmonellae alone led to a transient tu-
mor suppression (1 week to 10 days), and the tumors 
subsequently regrew. This may be because (i) there 
were too few bacteria in the tumor at the later stages, 
or (ii) immuno-evasive/tolerance mechanisms were 
activated to subvert the bacteria-mediated immune 
responses. Further studies are needed to confirm 
these hypotheses. Here, we showed that the period of 
tumor suppression was increased by combined 
treatment with recombinant IL-1β and Salmonellae, 
thereby confirming that IL-1β plays a crucial role in 
tumor suppression.  
MG1655 (LPS-competent E. coli) failed to elicit an 
effective anti-tumor response, presumably because 
the responses it did elicit were irrelevant in this con-
text. MG1655-treated tumors showed production of 
pro-IL-1β and pro-IL-18, but no significant expression 
of caspase-1, IL-1β, or IL-18. Thus, MG1655 may acti-
vate the TLR4 signaling pathway but not the inflam-
masome pathways required for IL-1β production. 
More detailed studies are underway to identify the 
mechanisms by which different bacterial strains acti-
vate the inflammasome pathway. 
We also detected increased numbers of macro-
phages and DCs in the spleen and draining lymph 
nodes as well as in the colonized tumors. The number 
of CD8+ T cells was significantly increased in 
ΔppGpp Salmonellae-colonized tumors, even during 
the early suppression stage. It is speculated that 
macrophages and DCs recruited to the draining 
lymph nodes may activate T cells. Considering the 
short period of tumor suppression, it is hard to con-
nect inhibited tumor growth with the adaptive re-
sponse triggered by CD8+ T cells infiltrating tumors 
colonized by ΔppGpp Salmonellae. Further studies are 
needed to elucidate the role of the adaptive immune 
response in this context.  
ΔppGpp Salmonellae is deficient in synthesis of 
ppGpp, the signal molecule absolutely required for 
expression of SPI1 genes as well as the rest of SPI 
genes [63] and thus is non-invasive. The reduction of 
tumor size was highly correlated with Salmonella 
persistence in tumor in suppression stage. In contrast, 
when the tumor re-grew again at re-growing stage, 
the number of tumor-colonizing bacteria decreased. 
The mechanism of immune response by ΔppGpp 
Salmonellae might be intriguing when compared with 
that of invasive tumor-colonizing Salmonellae such as 
A1R [64-67]. 
Conclusion 
Our results strongly suggest that TNF-α (se-
creted by macrophages) and IL-1β (secreted by vari-
ous innate immune cells, particularly DCs) are re-
sponsible for the anti-cancer effects of S. typhimurium. 
Unlike wild-type E. coli MG1655, attenuated ΔppGpp 
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Salmonellae triggered effective IL-1β/TNF-α-mediated 
immune responses in the tumor, leading to transient 
tumor regression. The main pathway responsible for 
IL-1β processing was the inflammasome, which in 
turn activated caspase-1, followed by the cleavage 
and secretion of active IL-1β and IL-18. The current 
study is the first to show that IL-1β plays a pivotal 
role in Salmonellae-mediated cancer therapy and pro-
vides a new paradigm of combined immunotherapy 
involving the administration of attenuated S. typhi-
murium plus a strategy to increase IL-1β activity. 
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